

Study type	Age	Study name and purpose	Location/ Sponsor	Contact/More info.	Basic inclusion criteria	Commitment	Status
Prevention	8+	Rituximab/Abatacept (RAPTOR study)	UCSF	clinicalresearch@diabetes.ucsf.edu 844-T1D-UCSF (844-813-8273)	Positive for 2 or more autoantibodies, impaired glucose tolerance; not diagnosed with T1D.	Weekly infusion of Rituximab for 4 weeks at UCSF followed by weekly injections of Abatacept at home. No placebo group! (everyone gets meds)	3/18/2021: study on-hold due to COVID
Prevention	3-45	Hydroxychloroquine	UCSF	clinicalresearch@diabetes.ucsf.edu 844-T1D-UCSF (844-813-8273) or clinicaltrials.gov	Positive for 2 or more autoantibodies; not diagnosed with T1D.	Blood test and a box of pills for at home.	3/18/2021 A few spots still available!
Prevention	2.5-45	TrialNet: Pathway to Prevention Antibody Screening. Determines risk for developing T1D in family members, providing opportunities to join in further trials if at-risk	Worldwide	www.trialnet.org or clinicaltrials.gov	Have a relative with T1D (siblings, cousins, etc. may be at a higher risk of developing T1D)	Blood test at a center or at home (to mail in or take to LabCorp)	3/18/2021 Available
Prevention	Any age	T1Detect: Antibody screening for anyone. To determine the risk for developing T1D	Worldwide	JDRF www.jdrf.org/t1d-resources/t1detect/	Screening for everyone	At home screening test kit for \$55.	4/6/2021 Available
Drug	14-45	Dompe: Oral Drug Ladarixin: thought to stop the inflammatory process and preserve beta cell function (like Teplizumab)	Center of Excellence in Diabetes, Sacramento	Dr. Prakasam (916) 426 1902 clinicaltrials.gov	T1D diagnosis in the last 100 days.	Five study visits over a year, oral pill to take at home	7/14/2021 Available
Drug/Cure	18-65	ViaCyte VC-01 - the study will implant stem cell derived precursor beta cells in encapsulated "pouches" under the skin. If effective, these cells will produce and allow insulin and other hormones into your bloodstream without immunosuppression	Diablo Clinical Research	Emily Galdes 925-930-7267 ext 226 egaldes@diablocinical.com	T1D for a minimum of 3 years.	A surgeon will implant up to 12 units through up to 6 small incisions in your skin. 18 visits over 2 years.	3/18/2021 full
Drug/Cure	18-65	Viacyte VC-02 - the study will implant stem cell derived precursor beta cells in "pouches" under the skin. If effective, these cells will produce and allow insulin and other hormones into your bloodstream.	UC Davis	Prasanth N. Surampudi, MD, Work: 916-734-8328, Cell: 973-768-4821. psurampudi@UCDAVIS.EDU Additional info: www.youtube.com/watch?v=yA9Dhnp6MA	For patients that are hypo unaware or who have diabetes that is not well managed.	A surgeon will implant up to 12 units through up to 6 small incisions in your skin. 18 visits over 2 years. Immunosuppression drugs will be provided.	4/19/2021 Available. Seeking 10 participants.
Drug/Cure	18-65	Vertex: An islet cell infusion with immunosuppression. The goal of this infusion is to provide replacement cells for the ones that have been lost or don't work properly in people with diabetes.	PA, MA, FL- travel provided	https://t1dstudy.com/ , https://www.clinicaltrials.gov/ct2/show/NCT04786262	Episodes of severe low blood sugar (hypoglycemia) and impaired hypoglycemic awareness. A1C 7-9.5	1.5 week hospital stay, 90 minute cell infusion, quarterly visits for five years. Half of the visits can be with a home health nurse, half at the clinical trial center. Immunosuppression drugs will be provided.	5/26/2021 Available. May open CA site.
Drug (celiac and T1D)	14-80	Latiglutenase Treatment in Type 1 Diabetes Patients with Celiac Disease. The goal is to evaluate the efficacy of an oral therapeutic agent in drink form for protecting individuals	Stanford	Franziska K Bishop: fbishop@stanford.edu, Nora Arrizon-Ruiz: narrizon@stanford.edu, or clinicaltrials.gov	T1D and Celiac and Celiac symptoms even with a gluten free diet	6 month study with an oral powder that mixes with water and periodic research visits.	03/18/2021 Available
Drug	18-25 (other sites up to 45)	TOPPLE T1D Testing to see if a plasmid injection can change the immune response, stopping the destruction of beta cells.	UCSF	clinicalresearch@diabetes.ucsf.edu 844-T1D-UCSF (844-813-8273)	Diagnosed within the past 4 years.	12 weekly injections.	03/18/2021 Available
Drug	8-17	PROTECT: Teplizumab Study	UCSF, Diablo	UCSF: clinicalresearch@diabetes.ucsf.edu 844-T1D-UCSF (844-813-8273), Diablo: 925-930-7267. Clinicaltrials.gov	Diagnosed with T1D in the last 21 days. No vaccinations within the last 8 weeks.	2 sets of 12 days infusions.	4/15/2021 Available at UCSF. On hold at Diablo.
Device/Drug	7-18	CLVer study. Hybrid closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes	Stanford	Eliana Frank: elianaf@stanford.edu, Dr. Bruce Buckingham: bbendo@stanford.edu. Clinicaltrials.gov	Within 3 weeks of diagnosis.	Physical exam, blood draws, possibly a daily pill. Will be provided Dexcom G6 CGM at no charge for most of a year.	4/15/2021 Available
Device	2-5	Tandem Control IQ	Stanford	Ryan Kingman: rkingman@stanford.edu Eliana Frank: elianaf@stanford.edu, Dr. Bruce Buckingham: bbendo@stanford.edu	Use of an insulin pump in the past 3 months. Use of Dexcom G6 for at least 11 out of the last 14 days.	Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their blood sugar.	4/15/2021 Available
Device	18-80	Medtronic Extended Wear Infusion Set Study. Evaluate a novel, long wear infusion set meant to last 6-7 days.	Stanford	diabetesresearch@stanford.edu, 408-655-8097	A1C under 8.5%. T1D at least 1 year. On 670G pump within 1 year prior to screening and willing to use auto mode and Guardian Sensor (3) during the	Participants will be given 12 experimental infusion sets to wear consecutively at home. 5 in-office visits, 2 phone calls.	
Device/Behavior	18-50	ONBOARD is for adults who are not currently using CGM (or using it but not consistently). The study provides 3 months of CGM supplies and testing out a behavioral intervention	Stanford (online)	onboardstudy@stanford.edu or Molly Tanenbaum, 650-725-3955 mollyt@stanford.edu	Not yet using CGM or not using CGM consistently.	Fully virtual study. Participants will be put in groups either "ONBOARD" or "CGM-only". Those in ONBOARD will schedule 4 60-minute sessions	4/19/2021 Available
Complications	18+	Various medications to treat painful diabetic neuropathy	Diablo Clinical Research	Caitlin Sheets: csheets@diablocinical.com	Experiencing painful diabetic neuropathy. A1C 7-10	Studies are 6-8 months long, with 9-13 clinic visits	3/23/21 Available
Behavior	18-70	T1D Exercise Initiative. Study provides a watch and collects information during 2.5 hours of weekly exercise. Study data will be used to inform algorithms and future	JAEB (at home study)	T1DEXI@jaeb.org, www.jaeb.org/t1dexi	T1D for more than 2 years Have or be willing to use Dexcom G6 CGM.	1 month at home study adding food/exercise info to an app, doing 6 short exercise videos / being active for 2 1/2 hours a week. Compensation provided.	10/21/2020 Available
Behavior	19-30	Act1on Diet Types Study for T1D	Stanford	Nora Arrizon- Ruiz, narrizon@stanford.edu Brianna Leverenz: bleveren@stanford.edu; 650-724-1778	T1D for more than 1 year A1C <13% BMI 25-39	10.5 months, 5 in-person visits. \$700 compensation.	11/13/2020 Available
Behavior	7-18	4T's study: 12-month clinical trial to see if increased contact with our team, technology use, frequent data review, and optional exercise modules can improve clinical outcomes	Stanford	Brianna Leverenz: bleveren@stanford.edu; 650-724-1778	Diagnosed within the last 31 days, and are currently being seen at Stanford Children's Hospital & Clinics.	Complete 6 surveys, wear CGM	10/5/2020 Available

Behavior	13-19	The Insul-In This Together Study: The study is a family-based intervention designed to support families with type 1 teens and improve family dynamics and T1d	Stanford (online)	insulinthistogether@stanford.edu	T1D teen and parent available.	Weekly 30 min. sessions held over 6 consecutive weeks. Surveys to complete online before, during, and after the sessions. A1C and CGM data to	3/18/21 Available
Behavior	19+	EMBARC: Stress reduction and glycemic control	UCSF	1-855-850-3599, embark@ucsf.edu	Anyone with T1D over 19 years old	Online surveys and blood draws quarterly. 1-2 workshops, 4 web meetings.	10/7/2020 Available
Behavior	1.5-8	PAIN1d Parent-Child Art Intervention for Navigating Type 1 Diabetes	UCSF	https://is.gd/ucsf_paint1d	Working with young children living with T1D and their caregivers to see whether we can contribute to reducing some of the stress that is common in	During COVID-19 restrictions, we are offering the art therapy sessions via Zoom.	5/24/2021 Available
Behavior	18+	Online survey on hypoglycemia events where it might have been nice to have someone there to help you	UCSF (web based)	Leslie Wilson, Leslie.Wilson@ucsf.edu, diabetespreference.ucsf.edu/study-information	Have T1D, be over the age of 18, have experienced hypoglycemic events	Online survey.	5/24/2021 Available